AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

NRIX · NASDAQ · Biotechnology

Nurix Therapeutics (NRIX)

Develops protein-degradation medicines through DEL-AI and large-pharma collaborations.

$25.70

vs last close+0.29 (+1.14%)

In millions of USD, except per-share figures

In millions	Q3 FY23Aug 2023	Q4 FY23Nov 2023	Q1 FY24Feb 2024	Q2 FY24May 2024	Q3 FY24Aug 2024	Q4 FY24Nov 2024	Q1 FY25Feb 2025	Q2 FY25May 2025	Q3 FY25Aug 2025	Q4 FY25Nov 2025	Q1 FY26Feb 2026	Q2 FY26May 2026
Revenue	18	15	17	12	13	13	18	44	8	14	6	9
Cost of revenue	48	50	50	49	55	67	70	78	5	5	84	4
Gross profit	−29	−35	−33	−37	−43	−54	−51	−34	3	9	−78	5
	11	11	12	12	12	11	12	14	94	92	15	99
Research & development	48	50	50	49	55	67	70	78	86	81	84	88
	11	11	12	12	12	11	12	14	13	14	15	16
General & administrative	11	11	12	12	12	11	12	14	13	14	15	16
Other expenses	−48	−50	−50	−49	−55	−67	−70	−78	−5	−3	−84	−4
Operating income	−40	−45	−45	−49	−55	−65	−63	−48	−91	−83	−92	−94
	3	3	4	4	6	6	7	6	5	5	5	4
Interest income	3	3	4	4	6	6	7	6	5	5	5	4
Other non-operating income	0	−3	−4	−4	−6	−6	−7	−6	−5	−5	−5	−4
Income before tax	−37	−42	−41	−44	−49	−59	−56	−43	−86	−78	−87	−90
Income tax expense	0	0	0	0	0	0	0	1	0	0	0	0
Net income from continuing operations	−37	−42	−42	−45	−49	−59	−56	−43	−86	−78	−87	−90
Net income	−37	−42	−42	−45	−49	−59	−56	−43	−86	−78	−87	−90
EPS, basic	−$0.68	−$0.77	−$0.76	−$0.71	−$0.67	−$0.75	−$0.67	−$0.52	−$1.03	−$0.82	−$0.79	−$0.81
EPS, diluted	−$0.68	−$0.77	−$0.76	−$0.71	−$0.67	−$0.75	−$0.67	−$0.52	−$1.03	−$0.82	−$0.79	−$0.81
Weighted average shares, basic	54	55	55	62	73	78	84	84	84	95	110	111
Weighted average shares, diluted	54	55	55	62	73	78	84	84	84	95	110	111
EBITDA	−38	−41	−39	−42	−46	−57	−54	−40	−81	−69	−83	−86
Depreciation & amortization	2	1	2	2	2	1	2	2	5	9	4	4
EBIT	−40	−42	−41	−44	−49	−59	−56	−43	−86	−78	−87	−90